A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

Neuracle Science

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Sudden Sensorineural Hearing Loss; Seneorineural Deafness

Treatments: Biological: NS101; Biological: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06249919

NS101_P2_04

Details and patient eligibility

About

The goal of this 2 step-up, exploratory study is to test safey, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage therapy.

The main questions it aims to answer are:

1. whether is it safe and tolerable when healthy volunteers and sudden sensorineural hearing loss patients take multiple doses of NS101 against FAM19A5
2. whether is it effective in reversing hearing capability in sudden sensorineural hearing loss patients who fails to show sufficient recovery despite of oral standard steroid therapy.

Patients and heathly volunteers will be given NS101 15mg/kg or 30mg/kg systemically less than 3 months per protocol.

This is placebo controlled, double blinded study, which means there will be a group who receives placebo (i.e. fake drug) for study purpose.

Enrollment: 118 estimated patients

Sex: All

Ages: 19 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Part A: healthy volunteers

Part B:

Inclusion Criteria:

• unilateral ideopathic SSNHL greater than 55dB at the average of 4 frequencies in PTA (contralateral hearing is less than 30dB)
• those who started standard treatment within 5 days after symptom onset
• those who were treated with oral steroids for 14 days, but incomplete recovery was confirmed as type III/IV according to Siegel's criteria at the end of the 14-day treatment

Exclusion Criteria:

• other otologic or systemic diseases
• retrocochlear lesion

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

118 participants in 4 patient groups, including a placebo group

Group A

Experimental group

Description:

NS101 15mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)

Treatment:

Biological: Placebo

Biological: NS101

Group B

Experimental group

Description:

NS101 30mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)

Treatment:

Biological: Placebo

Biological: NS101

Cohort A

Active Comparator group

Description:

NS101 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients

Treatment:

Biological: NS101

Cohort B

Placebo Comparator group

Description:

Placebo 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients

Treatment:

Biological: Placebo